IDH2 and glioma: While this remains the standard of care for IDH-mutant glioma, there is increasing evidence that co-occurring mutations (20) or pathway alteration of PI3K, mTOR or AKT may be present (21), highlighting that testing for IDH mutations alone is insufficient in this group of diffuse gliomas.